<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Granules India Ltd on Financial Report Insights</title>
    <link>https://reports.muthu.co/tags/granules-india-ltd/</link>
    <description>Recent content in Granules India Ltd on Financial Report Insights</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 15 Jul 2024 00:00:00 +0000</lastBuildDate>
    <atom:link href="https://reports.muthu.co/tags/granules-india-ltd/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Granules India Ltd - Annual Report 2023-24 Analysis</title>
      <link>https://reports.muthu.co/posts/granules-india-ltd/</link>
      <pubDate>Mon, 15 Jul 2024 00:00:00 +0000</pubDate>
      <guid>https://reports.muthu.co/posts/granules-india-ltd/</guid>
      <description>&lt;h2 class=&#34;heading&#34; id=&#34;overview&#34;&gt;&#xA;  Overview&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#overview&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;detailed-analysis&#34;&gt;&#xA;  Detailed Analysis&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#detailed-analysis&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;p&gt;This analysis looks into the Granules India Limited Annual Report for FY 2023-24, examining its financial performance, business segments, risk management, and ESG initiatives.&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;I. Financial Performance:&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;FY 2023-24 presented mixed results for Granules India. While revenue remained relatively flat compared to FY 2022-23 (₹45,064 million vs ₹45,119 million), the company demonstrated resilience amidst challenges.  Key financial highlights include:&lt;/p&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Revenue:&lt;/strong&gt;  Essentially flat year-over-year (YoY), impacted by a cyber incident and a decline in Paracetamol API sales.  However, a strategic shift towards higher-value formulations mitigated the overall impact.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;EBITDA:&lt;/strong&gt; Decreased YoY from ₹9,138 million to ₹8,560 million (19.0% margin vs 20.3% margin). This reduction is partly attributed to increased R&amp;amp;D expenditure.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Operating Cash Flow:&lt;/strong&gt;  Significantly lower YoY (₹4,394 million vs ₹7,387 million), primarily due to reduced EBITDA and extended inventory days.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Net Debt:&lt;/strong&gt; Increased marginally by ₹750 million to ₹8,421 million.  Capital expenditures of ₹3,788 million, mainly in Granules Life Sciences and Granules CZRO, contributed to this increase.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;R&amp;amp;D Expenditure:&lt;/strong&gt; Increased significantly YoY (₹1,986 million or 4.4% of revenue vs ₹1,164 million or 2.6% of revenue), demonstrating a commitment to future growth through innovation.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;ROCE:&lt;/strong&gt; 16.50%, indicating a moderate return on capital employed.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;II. Business Segments:&lt;/strong&gt;&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
